Title:
COMPOSITIONS COMPRISING AN ANTI-CA125 ANTIBODY AND A CYTOTOXIC COMPOUND AND THEIR USE FOR THE TREATMENT OF CANCER
Document Type and Number:
WIPO Patent Application WO2006099175
Kind Code:
A3
Abstract:
The present invention provides combination therapy methods, formulations and kits useful for managing or treating a CA 125-related disorder or symptom thereof. In one aspect, the present invention provides methods for managing or treating a cell proliferative disorder, such as a cancer, for example, ovarian cancer, comprising administering a combination of (a) a sensitizer, such as, for example, paclitaxel, and (b) an antibody that preferentially binds cell-associated CA 125 polypeptides relative to shed CA 125 polypeptides, hi some embodiments of the methods provided, the antibody is conjugated to a cytotoxic agent such as a radiolabel. In another aspect, the present invention provides pharmaceutical compositions comprising (a) a sensitizer; (b) an antibody that preferentially binds cell-associated CA 125 polypeptides relative to shed CA 125 polypeptides; and, (c) a pharmaceutically acceptable excipient, diluent, or carrier.
Inventors:
ALBONE EARL F (US)
Application Number:
PCT/US2006/008659
Publication Date:
December 14, 2006
Filing Date:
March 08, 2006
Export Citation:
Assignee:
EURO CELTIQUE SA (LU)
ALBONE EARL F (US)
ALBONE EARL F (US)
International Classes:
A61K39/395; A61P35/00
Domestic Patent References:
| WO2004035537A2 | 2004-04-29 |
Other References:
BERGER MARC A ET AL: "Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 20, no. 6, December 2005 (2005-12-01), pages 589 - 602, XP002394596, ISSN: 1084-9785
RUSTIN GORDON J S ET AL: "Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 JUN 2004, vol. 10, no. 11, 1 June 2004 (2004-06-01), pages 3919 - 3926, XP002394597, ISSN: 1078-0432
BLUMENTHAL R D ET AL: "TUMOR-SPECIFIC DOSE SCHEDULING OF BIMODAL RADIOIMMUNOTHERAPY AND CHEMOTHERAPY", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 23, no. 6C, 2003, pages 4613 - 4620, XP009036655, ISSN: 0250-7005
SINGLETON JUDITH ET AL: "Characterization of antibodies to CA 125 that bind preferentially to the cell-associated form of the antigen.", TUMOUR BIOLOGY : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ONCODEVELOPMENTAL BIOLOGY AND MEDICINE. 2006, vol. 27, no. 3, April 2006 (2006-04-01), pages 122 - 132, XP009070942, ISSN: 1010-4283
RUSTIN GORDON J S ET AL: "Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 JUN 2004, vol. 10, no. 11, 1 June 2004 (2004-06-01), pages 3919 - 3926, XP002394597, ISSN: 1078-0432
BLUMENTHAL R D ET AL: "TUMOR-SPECIFIC DOSE SCHEDULING OF BIMODAL RADIOIMMUNOTHERAPY AND CHEMOTHERAPY", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 23, no. 6C, 2003, pages 4613 - 4620, XP009036655, ISSN: 0250-7005
SINGLETON JUDITH ET AL: "Characterization of antibodies to CA 125 that bind preferentially to the cell-associated form of the antigen.", TUMOUR BIOLOGY : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ONCODEVELOPMENTAL BIOLOGY AND MEDICINE. 2006, vol. 27, no. 3, April 2006 (2006-04-01), pages 122 - 132, XP009070942, ISSN: 1010-4283
Download PDF: